Interstitial lung disease recurrence on chemotherapy rechallenge in breast cancer: a nationwide Japanese database.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-04-24 DOI:10.1080/14796694.2025.2495543

Soichiro Nishijima, Keiko Sato, Tomohiro Onoue, Wataru Hashimoto, Mayumi Shikano

{"title":"Interstitial lung disease recurrence on chemotherapy rechallenge in breast cancer: a nationwide Japanese database.","authors":"Soichiro Nishijima, Keiko Sato, Tomohiro Onoue, Wataru Hashimoto, Mayumi Shikano","doi":"10.1080/14796694.2025.2495543","DOIUrl":null,"url":null,"abstract":"Aim: The present study assessed the incidence of drug-induced interstitial lung disease (ILD) recurrence among breast cancer patients who underwent rechallenge with cancer-directed therapy.Materials & methods: Japanese insurance claims data and the Diagnosis Procedure Combination database (2009-2022) involving 81,601 patients were analyzed to evaluate 1,042 breast cancer patients who developed ILD. Of these, 566 patients underwent cancer-directed therapy rechallenge, and 42.1% of them were re-challenged with the same therapeutic regimen that caused the initial ILD.Results: ILD recurrence was observed in 18.9% of the patients, with a median recurrence time of 40 days. The drugs most commonly causing ILD were cytotoxic agents, and those most frequently used for rechallenge were cytotoxic agents.Conclusion: A notable ILD recurrence rate was observed in breast cancer patients after a cancer-directed therapy rechallenge, highlighting the need for cautious treatment planning and personalised strategies to balance cancer control while mitigating ILD risk.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":"21 12","pages":"1525-1535"},"PeriodicalIF":3.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077457/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2495543","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: The present study assessed the incidence of drug-induced interstitial lung disease (ILD) recurrence among breast cancer patients who underwent rechallenge with cancer-directed therapy.

Materials & methods: Japanese insurance claims data and the Diagnosis Procedure Combination database (2009-2022) involving 81,601 patients were analyzed to evaluate 1,042 breast cancer patients who developed ILD. Of these, 566 patients underwent cancer-directed therapy rechallenge, and 42.1% of them were re-challenged with the same therapeutic regimen that caused the initial ILD.

Results: ILD recurrence was observed in 18.9% of the patients, with a median recurrence time of 40 days. The drugs most commonly causing ILD were cytotoxic agents, and those most frequently used for rechallenge were cytotoxic agents.

Conclusion: A notable ILD recurrence rate was observed in breast cancer patients after a cancer-directed therapy rechallenge, highlighting the need for cautious treatment planning and personalised strategies to balance cancer control while mitigating ILD risk.

查看原文本刊更多论文

乳腺癌化疗再挑战的间质性肺疾病复发：日本全国数据库。

目的：本研究评估再次接受癌症定向治疗的乳腺癌患者中药物性间质性肺疾病（ILD）复发的发生率。材料与方法：分析日本保险索赔数据和诊断程序组合数据库（2009-2022）81,601例患者，对1,042例发生ILD的乳腺癌患者进行评估。其中，566例患者再次接受了癌症定向治疗，其中42.1%的患者再次接受了导致初始ILD的相同治疗方案。结果：18.9%的患者出现ILD复发，中位复发时间为40天。最常引起ILD的药物是细胞毒性药物，最常用于再挑战的药物是细胞毒性药物。结论：乳腺癌患者在接受癌症定向治疗后，ILD复发率显著升高，这表明需要谨慎的治疗计划和个性化的策略来平衡癌症控制，同时降低ILD风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.